Busulfan manufacturers and suppliers

Busulfan suppliers

Properties

Melting point:: 114-117 °C(lit.)

Boiling point:: 359.3°C (rough estimate)

Density: 1.305 (estimate)

refractive index: 1.5630 (estimate)

Flash point:: 9℃

storage temp.: Inert atmosphere,Room Temperature

solubility: Very slightly soluble in water, freely soluble in acetone and in acetonitrile, very slightly soluble in ethanol (96 per cent).

form: Crystalline Powder

color: Pale Brown

Water Solubility: Decomposes

Merck: 14,1505

BRN: 1791786

Stability:: Moisture Sensitive

Major Application: forensics and toxicology
veterinary

InChI: 1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

InChIKey: COVZYZSDYWQREU-UHFFFAOYSA-N

SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O

CAS DataBase Reference: 55-98-1(CAS DataBase Reference)

IARC: 1 (Vol. 4, Sup 7, 100A) 2012

EPA Substance Registry System: Busulfan (55-98-1)

Safety Information

Symbol(GHS): GHS06,GHS08

Signal word: Danger

Hazard statements: H301-H340-H350-H360FD

Precautionary statements: P202-P264-P270-P280-P301+P310-P405

Hazard Codes: T+,T,F

Risk Statements: 45-26/27/28-63-46-36/37/38-23/24/25-39/23/24/25-11

Safety Statements: 53-36/37/39-45-28A-36/37-16-7

RIDADR: UN 2811 6.1/PG 1

WGK Germany: 3

RTECS: EK1750000

HazardClass: 6.1(b)

PackingGroup: III

HS Code: 29053990

Storage Class: 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects

Hazard Classifications: Acute Tox. 3 Oral
Carc. 1A
Muta. 1B
Repr. 1B

Hazardous Substances Data: 55-98-1(Hazardous Substances Data)

Toxicity: LD50 i.v. in rats: 1.8 mg/kg (Scherf)

Limited Quantities: 5.0 kg (11 lbs) (solid)

Excepted Quantities: Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)

Use

Busulfan is a cytotoxic alkylating chemotherapeutic agent that is extensively used as preparative conditioning regimen prior to allogeneic HSCT for hematologic malignancies. Busulfan has been widely used in the treatment of CML and other hematologic malignancies and myelodysplastic disorders. The principal effect of busulfan is myelosuppression and myeloablation when used at the recommended dosage. Currently, busulfan is indicated for use in combination with cyclophosphamide to destroy cancer cells and make room for new bone marrow to grow prior to a bone marrow or peripheral blood progenitor cell replacement procedure. As a component of a conditioning regimen for HSCT, busulfan also suppresses the immune system so that the patient does not reject the new bone marrow.

You can find Busulfan suppliers, manufacturers, and distributors from countries such as CHINA, India and the United States here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.